19 results on '"Paitazoglou, Christina"'
Search Results
2. Lack of correlation between different congestion markers in acute decompensated heart failure
- Author
-
Haag, Svenja, Jobs, Alexander, Stiermaier, Thomas, Fichera, Carlo-Federico, Paitazoglou, Christina, Eitel, Ingo, Desch, Steffen, and Thiele, Holger
- Published
- 2023
- Full Text
- View/download PDF
3. The ALSTER-FLX Registry: 3-Month outcomes after left atrial appendage occlusion using a next-generation device, a matched-pair analysis to EWOLUTION
- Author
-
Paitazoglou, Christina, Meincke, Felix, Bergmann, Martin W., Eitel, Ingo, Fink, Thomas, Vireca, Elisa, Wohlmuth, Peter, Veliqi, Egzon, Willems, Stephan, Markiewicz, Agata, and Grygier, Marek
- Published
- 2022
- Full Text
- View/download PDF
4. Atrial Mechanics, Atrial Cardiomyopathy and Impact of Atrial Interventions.
- Author
-
KITTIPIBUL, VERAPRAPAS, LAUFER-PERL, MICHAL, BALAKUMARAN, KATHIR, COSTANZO, MARIA ROSA, MARWICK, THOMAS H., ALENEZI, FAWAZ, MOHAN, RAJEEV C., THOHAN, VINAY, BHATT, KUNJAN, FRIEDMANN, ROBERTO HODARA, SMART, FRANK, ECKMAN, PETER M., SARAON, TAJINDERPAL, BIEGUS, JAN, PAITAZOGLOU, CHRISTINA, HAMID, NADIRA, AMIN, ROHIT, TONG, ANN, and FUDIM, MARAT
- Abstract
• Atria make both active and passive contributions throughout the cardiac cycle. • Atrial cardiomyopathy is gaining recognition in various cardiac conditions and is associated with worse prognosis. • Alterations in atrial mechanics are associated with incident heart failure and atrial fibrillation. • Atrial interventions may have adverse subclinical effects on atrial mechanics, which could ultimately result in overt clinical symptoms. • Standardized assessment of atrial mechanics following atrial interventions might allow early detection and prevention of irreversible atrial remodeling. Our comprehension of atrial mechanics, atrial cardiomyopathy and their clinical implications across various cardiovascular conditions has advanced significantly. Atrial interventions can have differing effects on atrial mechanics. With the rapid increase in the use of atrial interventions, it is crucial for investigators and clinicians to acknowledge the potential adverse effects of these interventions on atrial mechanics that might not be clinically significant at the time of interventions. Recognizing the preclinical stage of atrial maladaptation might enable early interventions before the development of irreversible atrial remodeling and clinical manifestation. We review normal atrial function and mechanics, and atrial cardiomyopathy in select cardiovascular conditions. We also summarize and discuss the current evidence of the impact of various atrial interventions on atrial function and mechanics. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Treatment With an Interatrial Shunt in Heart Failure
- Author
-
Paitazoglou, Christina, primary, Bergmann, Martin W., additional, Kilicaslan, Baris, additional, Kilic, Teoman, additional, Bartunek, Jozef, additional, Pfister, Roman, additional, Iliadis, Christos, additional, Kaya, Ergun Baris, additional, and Ozdemir, Ramazan, additional
- Published
- 2024
- Full Text
- View/download PDF
6. Persistent and Recurrent Device-Related Thrombus After Left Atrial Appendage Closure
- Author
-
Mesnier, Jules, primary, Simard, Trevor, additional, Jung, Richard G., additional, Lehenbauer, Kyle R., additional, Piayda, Kerstin, additional, Pracon, Radoslaw, additional, Jackson, Gregory G., additional, Flores-Umanzor, Eduardo, additional, Faroux, Laurent, additional, Korsholm, Kasper, additional, Chun, Julian K.R., additional, Chen, Shaojie, additional, Maarse, Moniek, additional, Montrella, Kristi, additional, Chaker, Zakeih, additional, Spoon, Jocelyn N., additional, Pastormerlo, Luigi E., additional, Meincke, Felix, additional, Sawant, Abhishek C., additional, Moldovan, Carmen M., additional, Qintar, Mohammed, additional, Aktas, Mehmet K., additional, Branca, Luca, additional, Radinovic, Andrea, additional, Ram, Pradhum, additional, El-Zein, Rayan S., additional, Flautt, Thomas, additional, Ding, Wern Yew, additional, Sayegh, Bassel, additional, Benito-González, Tomás, additional, Lee, Oh-Hyun, additional, Badejoko, Solomon O., additional, Paitazoglou, Christina, additional, Karim, Nabeela, additional, Zaghloul, Ahmed M., additional, Agarwal, Himanshu, additional, Kaplan, Rachel M., additional, Alli, Oluseun, additional, Ahmed, Aamir, additional, Suradi, Hussam S., additional, Knight, Bradley P., additional, Alla, Venkata M., additional, Panaich, Sidakpal S., additional, Wong, Tom, additional, Bergmann, Martin W., additional, Chothia, Rashaad, additional, Kim, Jung-Sun, additional, Pérez de Prado, Armando, additional, Bazaz, Raveen, additional, Gupta, Dhiraj, additional, Valderrábano, Miguel, additional, Sanchez, Carlos E., additional, El Chami, Mikhael F., additional, Mazzone, Patrizio, additional, Adamo, Marianna, additional, Ling, Fred, additional, Wang, Dee Dee, additional, O’Neill, William, additional, Wojakowski, Wojtek, additional, Pershad, Ashish, additional, Berti, Sergio, additional, Spoon, Daniel B., additional, Kawsara, Akram, additional, Jabbour, George, additional, Boersma, Lucas V.A., additional, Schmidt, Boris, additional, Nielsen-Kudsk, Jens Erik, additional, Freixa, Xavier, additional, Ellis, Christopher R., additional, Fauchier, Laurent, additional, Demkow, Marcin, additional, Sievert, Horst, additional, Main, Michael L., additional, Hibbert, Benjamin, additional, Holmes, David R., additional, Alkhouli, Mohamad, additional, and Rodés-Cabau, Josep, additional
- Published
- 2023
- Full Text
- View/download PDF
7. Predicted impact of atrial flow regulator on survival in heart failure with reduced and preserved ejection fraction
- Author
-
Lauder, Lucas, primary, Bergmann, Martin W., additional, Paitazoglou, Christina, additional, Özdemir, Ramazan, additional, Iliadis, Christos, additional, Bartunek, Jozef, additional, Lauten, Alexander, additional, Keller, Thomas, additional, Weber, Stephan, additional, Sievert, Horst, additional, Anker, Stefan D., additional, and Mahfoud, Felix, additional
- Published
- 2023
- Full Text
- View/download PDF
8. PO-03-135 LEFT ATRIAL APPENDAGE OCCLUSION VERSUS STANDARD OF CARE IN PATIENTS WITH ATRIAL FIBRILLATION AND A PRIOR THROMBO-EMBOLIC EVENT DESPITE ORAL ANTICOAGULANT THERAPY: A PROPENSITY SCORE MATCHED COMPARISON
- Author
-
Maarse, Moniek, primary, Seiffge, David, additional, Aarnink, Errol, additional, Fierro, Nicolai, additional, Mazzone, Patrizio, additional, Beneduce, Alessandro, additional, Gasperetti, Alessio, additional, Tondo, Claudio, additional, Pracon, Radek, additional, Demkow, Marcin, additional, Zielinski, Kamil, additional, de Backer, Ole, additional, Korsholm, Kasper, additional, Nielsen-Kudsk, Jens Erik, additional, Estevez-Loureiro, Rodrigo, additional, Benito-Gonzalez, Tomas, additional, Nombela-Franco, Luis, additional, Simard, Trevor, additional, Alkhouli, Mohamad, additional, Holmes, David R., additional, Romeo, Maria Rita, additional, Berti, Sergio, additional, Millan, Xavier, additional, Arzamendi, Dabit, additional, Alla, Venkata M., additional, Paitazoglou, Christina, additional, Eitel, Ingo, additional, Freixa-Rofastes, Xavier, additional, Badejoko, Solomon, additional, Chothia, Rashaad A., additional, Kilic, Özlem, additional, Bergmann, Martin, additional, Spoon, Daniel, additional, Ram, Pradhum, additional, El-Chami, Mikhael F., additional, Branca, Luca, additional, Adamo, Marianna, additional, Danley, Kelsey, additional, Suradi, Hussam, additional, Swaans, Martin, additional, Werring, David, additional, and Boersma, Lucas V., additional
- Published
- 2023
- Full Text
- View/download PDF
9. Hemodynamic Assessment in Takotsubo Syndrome
- Author
-
Stiermaier, Thomas, primary, Reil, Jan-Christian, additional, Sequeira, Vasco, additional, Rawish, Elias, additional, Mezger, Matthias, additional, Pätz, Toni, additional, Paitazoglou, Christina, additional, Schmidt, Tobias, additional, Frerker, Christian, additional, Steendijk, Paul, additional, Reil, Gert-Hinrich, additional, and Eitel, Ingo, additional
- Published
- 2023
- Full Text
- View/download PDF
10. Effect of allogeneic adipose tissue derived mesenchymal stromal cell treatment in chronic ischemic heart failure with reduced ejection fraction – The SCIENCE Trial
- Author
-
Qayyum, Abbas Ali, Van Klarenbosch, Bas, Frljak, Sabina, Cerar, Andraz, Poglajen, Gregor, Traxler‐weidenauer, Denise, Nadrowski, Pawel, Paitazoglou, Christina, Vrtovec, Bojan, Bergmann, Martin W., Chamuleau, Steven A.j., Wojakowski, Wojtek, Gyöngyösi, Mariann, Kraaijeveld, Adriaan, Hansen, Kristian Schultz, Vrangbæk, Karsten, Jørgensen, Erik, Helqvist, Steffen, Joshi, Francis Richard, Johansen, Ellen Mønsted, Follin, Bjarke, Juhl, Morten, Højgaard, Lisbeth Drozd, Mathiasen, Anders Bruun, Ekblond, Annette, Haack‐sørensen, Mandana, Kastrup, Jens, Qayyum, Abbas Ali, Van Klarenbosch, Bas, Frljak, Sabina, Cerar, Andraz, Poglajen, Gregor, Traxler‐weidenauer, Denise, Nadrowski, Pawel, Paitazoglou, Christina, Vrtovec, Bojan, Bergmann, Martin W., Chamuleau, Steven A.j., Wojakowski, Wojtek, Gyöngyösi, Mariann, Kraaijeveld, Adriaan, Hansen, Kristian Schultz, Vrangbæk, Karsten, Jørgensen, Erik, Helqvist, Steffen, Joshi, Francis Richard, Johansen, Ellen Mønsted, Follin, Bjarke, Juhl, Morten, Højgaard, Lisbeth Drozd, Mathiasen, Anders Bruun, Ekblond, Annette, Haack‐sørensen, Mandana, and Kastrup, Jens
- Abstract
Background and Aims The aim of the SCIENCE trial was to investigate whether a single treatment with direct intramyocardial injections of adipose tissue derived mesenchymal stromal cells (CSCC_ASCs) was safe and improved cardiac function in patients with chronic ischemic heart failure with reduced ejection fraction (HFrEF). Methods The study was a European multi-centre double-blinded placebo-controlled phase II trial using allogeneic CSCC_ASCs from healthy donors or placebo (2:1 randomization). Main inclusion criteria were NYHA II-III, left ventricular ejection fraction (LVEF) < 45%, and NT-ProBNP levels>300 pg/mL. CSCC_ASCs or placebo (isotonic saline) were injected directly into viable myocardium. Primary endpoint was change in left ventricular end-systolic volume (LVESV) at 6 months follow up measured by echocardiography. Results A total of 133 symptomatic HFrEF patients were included. The treatment was safe without any drug-related severe adverse events or difference in cardiac related adverse events during a 3-years follow-up period. There were no significant differences between the groups during follow up in LVESV (0.3 ± 5.0 ml, P = 0.945), nor in secondary endpoints left ventricular end-diastolic volume (−2.0 ± 6.0 ml, P = 0.736) and LVEF (−1.6 ± 1.0%, P = 0.119). The NYHA classification improved slightly within the first year in both groups without any difference between groups. There were no changes in 6-Minute Walk Test, NT-ProBNP, CRP or quality-of-life the first year in any of the two groups. Conclusion The SCIENCE trial demonstrated safety of intramyocardial allogeneic CSCC_ASC therapy in patients with chronic HFrEF. However, it was not possible to improve the predefined endpoints and induce restoration of cardiac function or clinical symptoms, Aims The aim of the SCIENCE trial was to investigate whether a single treatment with direct intramyocardial injections of adipose tissue-derived mesenchymal stromal cells (CSCC_ASCs) was safe and improved cardiac function in patients with chronic ischaemic heart failure with reduced ejection fraction (HFrEF). Methods and results The study was a European multicentre, double-blind, placebo-controlled phase II trial using allogeneic CSCC_ASCs from healthy donors or placebo (2:1 randomization). Main inclusion criteria were New York Heart Association (NYHA) class II–III, left ventricular ejection fraction (LVEF) <45%, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels >300 pg/ml. CSCC_ASCs or placebo (isotonic saline) were injected directly into viable myocardium. The primary endpoint was change in left ventricular end-systolic volume (LVESV) at 6-month follow-up measured by echocardiography. A total of 133 symptomatic HFrEF patients were included. The treatment was safe without any drug-related severe adverse events or difference in cardiac-related adverse events during a 3-year follow-up period. There were no significant differences between groups during follow-up in LVESV (0.3 ± 5.0 ml, p = 0.945), nor in secondary endpoints of left ventricular end-diastolic volume (−2.0 ± 6.0 ml, p = 0.736) and LVEF (−1.6 ± 1.0%, p = 0.119). The NYHA class improved slightly within the first year in both groups without any difference between groups. There were no changes in 6-min walk test, NT-proBNP, C-reactive protein or quality of life the first year in any groups. Conclusion The SCIENCE trial demonstrated safety of intramyocardial allogeneic CSCC_ASC therapy in patients with chronic HFrEF. However, it was not possible to improve the pre-defined endpoints and induce restoration of cardiac function or clinical symptoms.
- Published
- 2023
11. Sex‐related differences in outcome after left atrial appendage occlusion: Insights from Europe and the EWOLUTION registry.
- Author
-
Paitazoglou, Christina, Eitel, Ingo, Stiermaier, Thomas, Ince, Hueseyin, Kische, Stephan, Pokushalov, Evgeny, Schmitz, Thomas, Schmidt, Boris, Gori, Tommaso, Meincke, Felix, Vireca, Elisa, Wohlmuth, Peter, Lucas, Boersma, and Bergmann, Martin W.
- Published
- 2023
- Full Text
- View/download PDF
12. Left atrial appendage closure in end‐stage renal disease and hemodialysis: Data from a German multicenter registry
- Author
-
Fink, Thomas, primary, Paitazoglou, Christina, additional, Bergmann, Martin W., additional, Sano, Makoto, additional, Keelani, Ahmad, additional, Sciacca, Vanessa, additional, Saad, Mohammed, additional, Eitel, Charlotte, additional, Heeger, Christian‐Hendrik, additional, Skurk, Carsten, additional, Landmesser, Ulf, additional, Thiele, Holger, additional, Stiermaier, Thomas, additional, Fuernau, Georg, additional, Reil, Jan‐Christian, additional, Frey, Norbert, additional, Kuck, Karl‐Heinz, additional, Tilz, Roland R., additional, Sandri, Marcus, additional, and Eitel, Ingo, additional
- Published
- 2023
- Full Text
- View/download PDF
13. Atrial Giant Cell Myocarditis as a Cause of Heart Failure
- Author
-
Paitazoglou, Christina, Bergmann, Martin W., Tiemann, Katharina, Wiese, Andrea, Schäfer, Ulrich, Schwarz, Arne, Eitel, Ingo, and Montenbruck, Moritz
- Subjects
atrial giant cell myocarditis ,AF, atrial fibrillation ,RA, right atrium ,heart failure ,Case Report ,TEE, transesophageal echocardiography ,HF, heart failure ,Ig, immunoglobulin ,LA, left atrium ,cardiac magnetic resonance ,Clinical Case ,CMR, cardiac magnetic resonance ,ANCA, antineutrophil cytoplasmic antibody ,cardiovascular system ,magnetic resonance imaging ,GCM, giant cell myocarditis ,Cardiology and Cardiovascular Medicine - Abstract
We present a patient with acute heart failure and new onset atrial fibrillation secondary to giant cell myocarditis with lone atrial involvement. The diagnosis was managed with cardiac magnetic resonance and confirmed by interventionally guided biopsy. In the future, diagnosis could be managed noninvasively for this rare entity as the gold standard. (Level of Difficulty: Advanced.), Graphical abstract
- Published
- 2022
14. Lack of correlation between different congestion markers in acute decompensated heart failure
- Author
-
Haag, Svenja, primary, Jobs, Alexander, additional, Stiermaier, Thomas, additional, Fichera, Carlo-Federico, additional, Paitazoglou, Christina, additional, Eitel, Ingo, additional, Desch, Steffen, additional, and Thiele, Holger, additional
- Published
- 2022
- Full Text
- View/download PDF
15. Intramyocardial injections of erythropoietin-analogue C.E.R.A. in ischemic cardiomyopathy: the ALSTER C.E.R.A. trial
- Author
-
Paitazoglou, Christina, primary, Bergmann, Martin W., additional, Losik, Denis, additional, Pokushalov, Evgeny, additional, Shabanov, Vitaly, additional, and Romanov, Alexander, additional
- Published
- 2022
- Full Text
- View/download PDF
16. True Efficacy of LAA Closure: Patient Outcomes on Long-term Single-Antiplatelet or No Therapy: Insights From the EWOLUTION Registry.
- Author
-
Paitazoglou, Christina, Bergmann, Martin W., Ince, Hüseyin, Kische, Stephan, Romanov, Aleksandr, Schmitz, Thomas, Schmidt, Boris, Gori, Tommaso, Meincke, Felix, Protopopov, Alexey Vladimir, Betts, Timothy, Vireca, Elisa, Wohlmuth, Peter, and Boersma, Lucas
- Published
- 2022
- Full Text
- View/download PDF
17. Left Atrial Appendage Occlusion vs Standard of Care After Ischemic Stroke Despite Anticoagulation.
- Author
-
Maarse M, Seiffge DJ, Werring DJ, Boersma LVA, Aarnink EW, Fierro N, Mazzone P, Beneduce A, Tondo C, Gasperetti A, Pracon R, Demkow M, Zielinski K, de Backer O, Korsholm K, Nielsen-Kudsk JE, Estévez-Loureiro R, Caneiro-Queija B, Benito-González T, de Prado AP, Nombela-Franco L, Salinas P, Holmes D, Almakadma AH, Berti S, Romeo MR, Alvarez XM, Arzamendi D, Alla VM, Agarwal H, Eitel I, Paitazoglou C, Freixa X, Cepas-Guillén P, Chothia R, Badejoko SO, Bergmann MW, Spoon DB, Maddux JT, El-Chami M, Ram P, Branca L, Adamo M, Suradi HS, van Dijk VF, Rensing BJWM, Zietz A, Paciaroni M, Caso V, Koga M, Toyoda K, Kallmünzer B, Cappellari M, Wilson D, Engelter S, and Swaans MJ
- Abstract
Importance: Patients with atrial fibrillation (AF) who have ischemic stroke despite taking oral anticoagulation therapy (OAT) have a very high risk of recurrence. Left atrial appendage occlusion (LAAO) is a mechanical stroke prevention strategy that may provide additional protection in patients with thromboembolic events under OAT., Objective: To compare percutaneous LAAO with continuing OAT alone regarding stroke prevention in patients with AF who had a thromboembolic event despite taking OAT., Design, Setting, and Participants: This cohort study was a propensity score-matched comparison of the STR-OAC LAAO cohort, an international collaboration of 21 sites combining patients from multiple prospective registries of patients who underwent LAAO between 2010 and 2022. STR-OAC LAAO cohort patients who had follow-up longer than 3 months were propensity score-matched to a previously published control cohort comprising patients from an established international collaboration of investigator-initiated prospective studies. This control cohort included patients with nonvalvular AF, recent ischemic stroke or transient ischemic attack, and follow-up longer than 3 months who were taking OAT before the index event. Analyses were adjusted for imbalances in gender, age, hypertension, diabetes, and CHA2 DS2-VASc score., Exposure: Left atrial appendage occlusion vs continuation of oral anticoagulation therapy alone (control group)., Main Outcomes and Measures: The primary outcome was time to first ischemic stroke., Results: Four hundred thirty-three patients from the STR-OAC LAAO cohort (mean [SD] age, 72 [9] years; 171 [39%] females and 262 [61%] males; mean [SD] CHA2 DS2-VASc score, 5.0 [1.6]) were matched to 433 of 1140 patients (38%) from the control group. During 2-year follow-up, 50 patients experienced ischemic stroke: an annualized event rate of 2.8% per patient-year in the STR-OAC LAAO group vs 8.9% per patient-year in the control group. Left atrial appendage occlusion was associated with a lower risk of ischemic stroke (hazard ratio, 0.33; 95% CI, 0.19-0.58; P < .001) compared with the control group. After LAAO, OAT was discontinued in 290 patients (67%), and the remaining 143 patients (33%) continued OAT after LAAO as an adjunctive therapy., Conclusions and Relevance: In patients with nonvalvular AF and a prior thromboembolic event despite taking OAT, LAAO was associated with a lower risk of ischemic stroke compared with continued OAT alone. Randomized clinical trial data are needed to confirm that LAAO may be a promising treatment option for this population with a very high risk of stroke.
- Published
- 2024
- Full Text
- View/download PDF
18. ALSTER-TAVR 2024: clinical results at one year following optimized self-expanding, transcatheter aortic valve peplacement employing the cusp-overlay technique.
- Author
-
Bergmann MW, Krause JM, Schofer N, Meincke F, Paitazoglou C, Heeger CH, Willems S, Hakmi S, and Tigges E
- Abstract
Objectives: Atrioventricular (AV) conduction disturbances are still common following transcatheter aortic valve replacement (TAVR). The study evaluates the feasibility and clinical effect of self-expanding (SE)-TAVR employing an optimized cusp-overlay technique (COT) at 1 year in a German all-comers population., Methods: We analyzed 1-year clinical outcomes in patients who received a SE valve employing the optimized COT. Consecutive patients who underwent SE-TAVR (EvolutR, EvolutPRO) after introduction of the COT as the default implantation technique in 2020 were included (n = 101). Consecutive TAVR patients from the same operators using the conventional implantation technique (CIT) served as the control group (n = 116)., Results: The COT was successfully performed in more than 80% of the patients in the COT group. (81.2%, n = 82/101). At discharge, no difference regarding AV block of at least II (CIT 19.47% vs COT 21%; P = .86) and permanent pacemaker (PPM) implantation (CIT 17.5% vs COT 19%; P = .73) was observed between the cohorts. New left bundle branch block (LBBB) was significantly less frequent in the COT group (CIT 40.71% vs COT 26%; P = .029). Paravalvular leakage (PVL) greater than I° was reduced in the COT cohort (CIT 8.62% vs COT 0.99%; P = .012). There was no significant difference in mortality (CIT 18.27% vs COT 13.83%; P = .44), stroke (CIT 9.62% vs COT 15.96%; P = .16) or cardiovascular rehospitalization after 1 year (CIT 25.96% vs 24.47%; P = .92) between the groups., Conclusions: Implementation of COT-TAVR was feasible and safe, and it resulted in an improvement of TAVR outcomes regarding PVL greater than I° and new onset LBBB. However, with respect to PPM, no difference was observed 1-year post-TAVR.
- Published
- 2024
- Full Text
- View/download PDF
19. Effect of allogeneic adipose tissue-derived mesenchymal stromal cell treatment in chronic ischaemic heart failure with reduced ejection fraction - the SCIENCE trial.
- Author
-
Qayyum AA, van Klarenbosch B, Frljak S, Cerar A, Poglajen G, Traxler-Weidenauer D, Nadrowski P, Paitazoglou C, Vrtovec B, Bergmann MW, Chamuleau SAJ, Wojakowski W, Gyöngyösi M, Kraaijeveld A, Hansen KS, Vrangbaek K, Jørgensen E, Helqvist S, Joshi FR, Johansen EM, Follin B, Juhl M, Højgaard LD, Mathiasen AB, Ekblond A, Haack-Sørensen M, and Kastrup J
- Subjects
- Humans, Chronic Disease, Quality of Life, Stroke Volume, Treatment Outcome, Ventricular Function, Left, Double-Blind Method, Heart Failure, Hematopoietic Stem Cell Transplantation, Mesenchymal Stem Cells
- Abstract
Aims: The aim of the SCIENCE trial was to investigate whether a single treatment with direct intramyocardial injections of adipose tissue-derived mesenchymal stromal cells (CSCC_ASCs) was safe and improved cardiac function in patients with chronic ischaemic heart failure with reduced ejection fraction (HFrEF)., Methods and Results: The study was a European multicentre, double-blind, placebo-controlled phase II trial using allogeneic CSCC_ASCs from healthy donors or placebo (2:1 randomization). Main inclusion criteria were New York Heart Association (NYHA) class II-III, left ventricular ejection fraction (LVEF) <45%, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels >300 pg/ml. CSCC_ASCs or placebo (isotonic saline) were injected directly into viable myocardium. The primary endpoint was change in left ventricular end-systolic volume (LVESV) at 6-month follow-up measured by echocardiography. A total of 133 symptomatic HFrEF patients were included. The treatment was safe without any drug-related severe adverse events or difference in cardiac-related adverse events during a 3-year follow-up period. There were no significant differences between groups during follow-up in LVESV (0.3 ± 5.0 ml, p = 0.945), nor in secondary endpoints of left ventricular end-diastolic volume (-2.0 ± 6.0 ml, p = 0.736) and LVEF (-1.6 ± 1.0%, p = 0.119). The NYHA class improved slightly within the first year in both groups without any difference between groups. There were no changes in 6-min walk test, NT-proBNP, C-reactive protein or quality of life the first year in any groups., Conclusion: The SCIENCE trial demonstrated safety of intramyocardial allogeneic CSCC_ASC therapy in patients with chronic HFrEF. However, it was not possible to improve the pre-defined endpoints and induce restoration of cardiac function or clinical symptoms., (© 2023 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.